Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

被引：0
作者：
Berardi, R. [1 ]
Torniai, M. [1 ]
Pusceddu, S. [2 ]
Spada, F. [3 ]
Brizzi, M. P. [4 ]
Ibrahim, T. [5 ]
Antonuzzo, L. [6 ]
Ferolla, P. [7 ]
Panzuto, F. [8 ]
Silvestris, N. [9 ]
Partelli, S. [10 ]
Bongiovanni, A. [5 ]
Zichi, C. [4 ]
Riva, N. [5 ]
Rinzivillo, M. [8 ]
机构：
[1] Univ Politecn Marche, Ancona, Italy
[2] INT, Milan, Italy
[3] IEO, Milan, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[6] AOU Careggi, Florence, Italy
[7] Osped S Maria Misericordia, Perugia, Italy
[8] Sapienza Univ Rome, St Andrea Hosp, Sch Med, Rome, Italy
[9] Cancer Inst Giovanni Paolo II, Bari, Italy
[10] Univ Vita & Salute, Osped San Raffaele IRCCS, Milan, Italy
来源：
NEUROENDOCRINOLOGY | 2016年 / 103卷
关键词：
PNET; Dose intensity; Targeted therapy; Everolimus; Cumulative dose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
L2
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [41] Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors
    Lee, Lingaku
    Ito, Tetsuhide
    Igarashi, Hisato
    Miki, Masami
    Fujimori, Nao
    Kawabe, Ken
    Jensen, Robert T.
    Ogawa, Yoshihiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 163 - 169
  • [42] DOSE INTENSITY
    OZOLS, RF
    THIGPEN, JT
    DAUPLAT, J
    COLOMBO, N
    PICCART, MJ
    BERTELSEN, K
    LEVIN, L
    LUND, B
    ANNALS OF ONCOLOGY, 1993, 4 : 49 - 56
  • [43] Imaging of pancreatic neuroendocrine tumors
    Berger, Frank
    Ingenerf, Maria
    Auernhammer, Christoph J.
    Cyran, Clemens
    Ebner, Ricarda
    Zacherl, Mathias
    Ricke, Jens
    Schmid-Tannwald, Christine
    RADIOLOGIE, 2024, 64 (07): : 559 - 567
  • [44] Sunitinib in pancreatic neuroendocrine tumors
    Raymond, Eric
    Hammel, Pascal
    Dreyer, Chantal
    Maatescu, Christian
    Hentic, Olivia
    Ruszniewski, Philippe
    Faivre, Sandrine
    TARGETED ONCOLOGY, 2012, 7 (02) : 117 - 125
  • [45] Pancreatic neuroendocrine tumors: a review
    Young, Kate
    Iyer, Ridhima
    Morganstein, Daniel
    Chau, Ian
    Cunningham, David
    Starling, Naureen
    FUTURE ONCOLOGY, 2015, 11 (05) : 853 - 864
  • [46] Pancreatic Neuroendocrine Tumors: an Update
    Alessandro Paniccia
    Barish H. Edil
    Richard D. Schulick
    Indian Journal of Surgery, 2015, 77 : 395 - 402
  • [47] A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors
    Dasari, A.
    Qiao, W.
    Halperin, D.
    Stanietzky, N.
    Surabhi, V
    Phillips, M.
    Sakamuri, D.
    Wilson, K.
    Leung, M.
    Smack, M.
    Yao, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 232 - 232
  • [48] RETRACTED ARTICLE: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
    Jun Yao
    Jian-yao Wang
    Yi Liu
    Bin Wang
    Ying-xue Li
    Ru Zhang
    Li-Sheng Wang
    Lei Liu
    Medical Oncology, 2014, 31
  • [49] Sunitinib in pancreatic neuroendocrine tumors
    Eric Raymond
    Pascal Hammel
    Chantal Dreyer
    Christian Maatescu
    Olivia Hentic
    Philippe Ruszniewski
    Sandrine Faivre
    Targeted Oncology, 2012, 7 : 117 - 125
  • [50] Genetics of Pancreatic Neuroendocrine Tumors
    Mohindroo, Chirayu
    McAllister, Florencia
    De Jesus-Acosta, Ana
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (05) : 1033 - 1051
12345